Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence (CLOSE)
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
A patent foramen ovale (PFO) is found more frequently in patients with an ischemic stroke than in control subjects.
Therapeutic options to prevent stroke recurrence include antiplatelet drugs, oral anticoagulants, and transcatheter closure of the foramen. However, there are no published studies showing convincingly the superiority of any one of these strategies in preventing stroke recurrence.
The aim of this randomized clinical trial is to assess whether chronic anticoagulation on the one hand and transcatheter on the other hand are superior to chronic antiplatelet therapy in preventing stroke recurrence.
| Condition | Intervention | Phase |
|---|---|---|
|
Ischemic Stroke Patent Foramen Ovale Atrial Septal Aneurysm Migraine |
Drug: aspirin Drug: Antivitamins K Device: Devices for PFO closure |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Closure of Patent Foramen Ovale or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence |
- stroke(fatal or not) [ Time Frame: during the follow up (between 3 or 5 years) ] [ Designated as safety issue: Yes ]
- Disabling stroke [ Time Frame: during the follow-up ] [ Designated as safety issue: Yes ]
- Ischemic stroke [ Time Frame: during the follow-up ] [ Designated as safety issue: Yes ]
- Cerebral haemorrhage [ Time Frame: during the follow-up ] [ Designated as safety issue: Yes ]
- Ischemic stroke, TIA, or systemic embolism [ Time Frame: during the follow-up ] [ Designated as safety issue: Yes ]
- Death (all causes) [ Time Frame: during the follow-up ] [ Designated as safety issue: Yes ]
- Vascular death [ Time Frame: during the follow-up ] [ Designated as safety issue: Yes ]
- Moderate to severe bleeding complications [ Time Frame: during the follow-up ] [ Designated as safety issue: Yes ]
- Procedural or device complications [ Time Frame: within 30 days ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 900 |
| Study Start Date: | December 2007 |
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: 1 |
Drug: aspirin
during the follow up
Other Names:
|
| Experimental: 2 |
Drug: Antivitamins K
during the follow up
Other Name: Antivitamins K
|
| Experimental: 3 |
Device: Devices for PFO closure
endovascular treatment no longer than 21 days after the random.
Other Names:
|
Detailed Description:
Secondary prevention for stroke patients with PFO is a subject of considerable debate. Therapeutic options include antiplatelet drugs, oral anticoagulants, and transcatheter closure of the foramen. There are no published studies showing convincingly the superiority of any one of these strategies in preventing stroke recurrence. All the therapeutic options have some risks and unless randomised trials can define who should be treated with what (if anything), and for how long, we could end up exposing patients to unnecessary complications of treatment.
The primary objective of this study is to assess whether chronic anticoagulation (INR 2 to 3) on the one hand and endovascular treatment on the other hand are superior to chronic antiplatelet therapy in preventing stroke recurrence in young (16 to 60 years) patients with a PFO (> 30 microbubbles or associated with an atrial septal aneurysm) and an otherwise unexplained ischaemic stroke.
Secondary objectives of the study are:
- to evaluate the safety of the three therapeutic options, in terms of major drug-, device- or procedure-related complications, in order to allow a benefit/risk assessment of each therapeutic option in this population.
- to assess the rate of technical success and effectiveness of endovascular procedure to treat PFO and ASA.
Eligibility| Ages Eligible for Study: | 16 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female, 16 <= age <= 60 ans.
- Recent (<= 6 months) ischemic stroke documented by CT-san or MRI (whatever the duration of symptoms: shorter or longer than 24 hours).
- Modified Rankin score <=3.
- Absence of any other identifiable cause of stroke
Presence of a PFO with at least one of the following characteristics:
- right-to-left shunt > 30 microbubbles, at rest or during provocative manoeuvres, by TTE ou TOE
- associated ASA (base ≥ à 15 mm, total excursion > à 10 mm) by TOE
- Informed consent.
Exclusion Criteria:
- Any identifiable cause of ischemic stroke other than PFO.
- Isolated atrial septal defect or atrial septal defect associated with PFO with significant left-to-right shunt requiring closure.
- Previous surgical or endovascular treatments of PFO or ASA.
- Known or suspected pregnancy (beta hCG test must be performed before inclusion).
- Women who are breast-feeding.
- Inability to comply with the treatments or follow-up requirements of the study.
- No affiliation to the national health service.
- Presence of other medical problems that would either lead to inability to complete the trial or interfere with the assessment of outcomes.
- Participation in another study.
- Unable to understand the full meaning of the informed consent.
Related medical treatments of the trial:
- Long-term oral anticoagulation or antiplatelet therapy is indicated for another disease.
Contra-indication to antiplatelet therapy or oral anticoagulants :
- 3-arm trial : contra-indication to aspirin or clopidogrel or antivitamins K
- 2-arm trial (closure vs antiplatelet therapy) : contra-indication to aspirin or clopidogrel
- 2-arm trial (antivitamins K vs antiplatelet therapy : contra-indication to antivitamins K or to any antiplatelet drug
- Increased risk of bleeding, such as severe hepatic insufficiency, current peptic ulceration, proliferative diabetic retinopathy, history of severe systemic bleeding (e.g. gastrointestinal bleeding, gross hematuria, intraocular bleeding, hemorrhagic stroke, or intracranial hemorrhage), or other history of bleeding diathesis or coagulopathy.
Related to endovascular treatments :
- Infection requiring antibiotics (inclusion is possible after healing, 4 weeks after withdrawal of antibiotics).
- Very large or multi-perforated ASA for which endovascular treatments is deemed too risky.
- Presence of thrombus or occlusion between the venous access and the right atrium.
- Presence of an inferior vena cava filter.
- Severe pulmonary hypertension.
Contacts and Locations| France | |
| Hôpital Saint-Anne | Recruiting |
| Paris, France | |
| Contact: Jean-Louis MAS +33145658284 jl.mas@ch-sainte-anne.fr | |
| Principal Investigator: Jean Louis MAS | |
| Principal Investigator: | MAS Jean-Louis, MD, PhD | Centre hospitalier sainte Anne |
More Information
No publications provided
| Responsible Party: | Assistance Publique - Hôpitaux de Paris |
| ClinicalTrials.gov Identifier: | NCT00562289 History of Changes |
| Other Study ID Numbers: | P060406 |
| Study First Received: | November 21, 2007 |
| Last Updated: | December 11, 2012 |
| Health Authority: | France: Ministry of Health |
Keywords provided by Assistance Publique - Hôpitaux de Paris:
|
Stroke Patent Foramen Ovale Atrial septal aneurysm Antiplatelet therapy |
Oral anticoagulants Transcatheter closure Migraine |
Additional relevant MeSH terms:
|
Aneurysm Foramen Ovale, Patent Heart Septal Defects, Atrial Recurrence Stroke Cerebral Infarction Migraine Disorders Vascular Diseases Cardiovascular Diseases Heart Septal Defects Heart Defects, Congenital Cardiovascular Abnormalities Heart Diseases Congenital Abnormalities Disease Attributes |
Pathologic Processes Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Brain Infarction Brain Ischemia Headache Disorders, Primary Headache Disorders Aspirin Aspirin, dipyridamole drug combination Dipyridamole 4-Hydroxycoumarins Vitamin K Antivitamins K |
ClinicalTrials.gov processed this record on May 19, 2013